Business Context and Reporting Period
Company: InfuSystem Holdings, Inc. (formerly HAPC, Inc.)
Filing Date: October 25, 2007
Event: Completion of the acquisition of InfuSystem, Inc. from I-Flow Corporation. The Company, previously a blank check shell company, ceased to be a shell company upon closing. The Company changed its name from HAPC, Inc. to InfuSystem Holdings, Inc. effective October 25, 2007.
Key Financial Metrics and Transaction Terms
- Total Purchase Price: $100,000,000 for all issued and outstanding capital stock of InfuSystem.
- Payment Structure:
- Cash: $67,297,000
- Financing (Loan from I-Flow): $32,703,000
- Contingent Consideration: Potential additional payment of up to $12,000,000 payable in 2011. This is based on the Company achieving a consolidated net revenue Compound Annual Growth Rate (CAGR) of at least 40% over the three-year period ended December 31, 2010, compared to InfuSystem's 2007 net revenues. The maximum payment requires a 50% CAGR.
- Debt and Security: The Company and its subsidiary granted I-Flow a first priority security interest in all property and assets to secure the $32,703,000 loan.
- Shareholder Conversions: 2,816,488 shares were converted at $6.00 per share.
Material Changes and Agreements
The filing details several material definitive agreements entered into on October 25, 2007:
- Services Agreement: InfuSystem will continue to provide billing, collection, and management services to I-Flow. Fees are the greater of (i) employee expenses plus 40% or (ii) 25% of net cash collections. Initial term is 3 years with automatic 1-year renewals.
- License Agreement: InfuSystem granted I-Flow a perpetual, royalty-free license to use its intellectual property. The license is exclusive for acute post-operative pain management and non-exclusive for other fields (e.g., wound site management).
- Board Representation: Great Point Partners, LLC (holding 26.9% of stock) secured the right to designate one director to the Board of Directors as long as they own at least 10% of voting securities.
- Management Changes: Steven Watkins was appointed Chief Executive Officer and Director. John Voris stepped down as CEO but remains a non-executive director. Erin Enright resigned as Chief Financial Officer.
Outlook, Risks, and Contingencies
- Revenue Targets: Future cash outflows are contingent on meeting aggressive revenue growth targets (40% to 50% CAGR) to trigger the earn-out payment.
- Related Party Transactions: Significant ongoing financial relationships with I-Flow (seller) via the Services Agreement and Credit Agreement.
- Dividend Policy: The Company does not intend to pay dividends in the foreseeable future; earnings will be retained for operations or share repurchases.
- Financial Data: The filing does not provide specific revenue, profit, or cash flow numbers for the current period. Historical financial data for InfuSystem is incorporated by reference from the Definitive Proxy Statement and Form 10-Q.
Investor Verification Checklist
- Verify the specific terms and performance metrics of the $12,000,000 contingent consideration in the Stock Purchase Agreement.
- Review the "Acquisition Financing" section of the Definitive Proxy Statement for full details on the $32,703,000 loan covenants.
- Confirm the financial impact of the Services Agreement fees on future operating margins.
- Examine the unaudited pro forma financial statements (Exhibit 99.6) to understand the combined entity's financial position.
- Monitor the status of the 2,816,488 converted shares and the impact on total outstanding share count.